抗反转录病毒药物与瑞士HIV队列中亚临床冠状动脉疾病的相关性
在瑞士HIV队列研究≥45岁参与者中开展冠状动脉钙化评分与冠状动脉CT血管造影,分析10种最常用抗反转录病毒药物的累积暴露与亚临床冠状动脉疾病终点之间的关联。结果显示非钙化/混合斑块仅与阿巴卡韦暴露呈正相关,恩曲他滨、替诺福韦二吡呋酯与依非韦伦则分别与部分终点呈负相关。
要点
- 非钙化/混合斑块风险升高仅见于阿巴卡韦暴露者。
- 恩曲他滨、替诺福韦二吡呋酯和依非韦伦与部分亚临床CAD终点呈负相关。
- 节段受累评分与节段严重程度评分与任何药物均无关联。
核心结论
- 非钙化/混合斑块风险升高仅见于阿巴卡韦暴露患者,恩曲他滨与其呈负相关,替诺福韦二吡呋酯和依非韦伦分别与任何斑块和钙化斑块呈负相关。
研究设计与样本
- 瑞士HIV队列研究中≥45岁参与者接受冠状动脉钙化评分与冠状动脉CT血管造影,共403例。
- 采用逆概率治疗加权(IPTW)的logistic回归模型,分析亚临床CAD与10种最常用药物累积暴露的关联。
主要发现
- 冠状动脉钙化评分>0者188例(47%),任何斑块214例(53%),钙化斑块151例(38%),非钙化/混合斑块150例(37%)。
- 冠状动脉钙化评分>0与依非韦伦(每5年IPTW校正OR 0.73,95%CI 0.56-0.96)、替诺福韦二吡呋酯(0.68,95%CI 0.49-0.95)、洛匹那韦(0.64,95%CI 0.43-0.96)呈负相关。
- 任何斑块与替诺福韦二吡呋酯呈负相关(0.71,95%CI 0.51-0.99),钙化斑块与依非韦伦呈负相关(0.7,95%CI 0.57-0.97)。
- 非钙化/混合斑块与阿巴韦韦呈正相关(1.46,95%CI 1.08-1.98),与恩曲他滨呈负相关(0.67,95%CI 0.46-0.99)。
- 节段严重程度评分(SSS)与节段受累评分(SIS)与任何药物均无关联。
关键数值与推荐
- 冠状动脉钙化评分>0:依非韦伦每5年IPTW校正OR 0.73(95%CI 0.56-0.96)。
- 冠状动脉钙化评分>0:替诺福韦二吡呋酯每5年IPTW校正OR 0.68(95%CI 0.49-0.95)。
- 冠状动脉钙化评分>0:洛匹那韦每5年IPTW校正OR 0.64(95%CI 0.43-0.96)。
- 任何斑块:替诺福韦二吡呋酯每5年IPTW校正OR 0.71(95%CI 0.51-0.99)。
- 非钙化/混合斑块:阿巴卡韦每5年IPTW校正OR 1.46(95%CI 1.08-1.98),恩曲他滨0.67(95%CI 0.46-0.99)。
临床怎么用
- 对接受阿巴卡韦治疗且心血管风险较高的HIV感染者,可关注非钙化/混合斑块相关亚临床动脉粥样硬化评估。
- 依非韦伦、替诺福韦二吡呋酯、恩曲他滨与部分亚临床CAD终点呈负相关,解读时需结合整体心血管风险评估。
局限性
- 原文摘要未报告研究局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary artery disease (CAD) events have been associated with certain antiretroviral therapy (ART) agents. In contrast, the influence of ART on subclinical atherosclerosis is not clear. The study objective was to assess the association between individual ART agents and the prevalence and extent of subclinical CAD. METHODS: Coronary artery calcium (CAC) scoring and coronary computed tomography angiography (CCTA) were performed in ≥45-year-old Swiss Human Immunodeficiency Virus Cohort Study participants. The following subclinical CAD endpoints were analyzed separately: CAC score >0, any plaque, calcified plaque, noncalcified/mixed plaque, segment involvement score (SIS), and segment severity score (SSS). Logistic regression models calculated by inverse probability of treatment weights (IPTW) were used to explore associations between subclinical CAD and cumulative exposure to the 10 most frequently used drugs. RESULTS: There were 403 patients who underwent CCTA. A CAC score >0 was recorded in 188 (47%), any plaque in 214 (53%), calcified plaque in 151 (38%), and noncalcified/mixed plaque in 150 (37%) participants. A CAC score >0 was negatively associated with efavirenz (IPTW adjusted odds ratio per 5 years 0.73, 95% confidence interval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95), and lopinavir (0.64, 95% CI 0.43-0.96). Any plaque was negatively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99). Calcified plaque was negatively associated with efavirenz (0.7, 95% CI 0.57-0.97). Noncalcified/mixed plaque was positively associated with abacavir (1.46, 95% CI 1.08-1.98) and negatively associated with emtricitabine (0.67, 95% CI 0.46-0.99). For SSS and SIS, we found no association with any drug. CONCLUSIONS: An increased risk of noncalcified/mixed plaque was only found in patients exposed to abacavir. Emtricitabine was negatively associated with noncalcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negatively associated with any plaque and calcified plaque, respectively.
引用
- Kovari H, Calmy A, Doco-Lecompte T, et al. Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis. 2020. PMID: 30958888. doi:10.1093/cid/ciz283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。